Subscribe
Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

JAMA Editor’s Summary

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
June 26, 2018
ADVERTISEMENT
DOCSF21

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 26, 2018 issue

ADVERTISEMENT
DOCSF21

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

HealthXLGet Health